Clinical Research

Combination has impact in kidney cancer

An experimental cancer therapy that combines the Roche checkpoint antibody Tecentriq (atezolizumab) and Avastin (bevacizumab) met its co-primary endpoint of progression-free survival in a Phase 3 trial of patients with metastatic renal cell carcinoma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Innate Pharma, MedImmune to trial cancer combo

A new agreement for fighting cancer by targeting the tumour microenvironment has been announced by the AstraZeneca Plc unit MedImmune and Innate Pharma SA of France. The goal is to overcome some of the limitations of the current checkpoint inhibitors.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Pixium Vision says bionic vision system helped patient

The first patient to be treated with a wireless sub-retinal implant designed to correct for damage caused by dry age-related macular degeneration (AMD) has responded to the therapy, according to the developer Pixium Vision SA of France.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Adocia reports data from diabetes combination therapy

France-based Adocia SA has reported positive early results from a new formulation of existing diabetes medicines that is intended to act faster and last longer than the current standard of care.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

AstraZeneca says triple COPD therapy works

An experimental therapy for chronic obstructive pulmonary disease (COPD) which combines three compounds into single treatment has delivered statistically significant results in a Phase 3 trial, according to AstraZeneca Plc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Novartis migraine drug gives relief

Novartis has reported positive results from a late-stage clinical trial showing that its monoclonal antibody erenumab provided relief to patients with migraine who have been unsuccessful in treating their disease with two to four other therapies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

BMS reports data for IO combination

Bristol-Myers Squibb Co has reported positive results for a checkpoint inhibitor combination therapy in patients with a specific type of metastatic colorectal cancer. It combines Opdivo (nivolumab), a PD-1 inhibitor, and Yervoy (ipilimumab), an inhibitor of CTLA-4.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

PharmaMar ovarian cancer trial fails

A Phase 3 trial of a novel anticancer drug developed by Spain’s PharmaMar SA for platinum-resistant ovarian cancer failed to reach its primary endpoint of progression free survival compared with topotecan chemotherapy or liposomal doxorubicin. The drug, Zepsyre (lurbinectedin), inhibits RNA polymerase II.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Spain

Nanobiotix reports data in liver cancer

An early-stage trial of a medicine designed to enhance the effects of radiotherapy has produced promising data from patients with liver cancers. The medicine, NBTXR3, achieved a complete response in three out of seven patients who were eligible for evaluation.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

iTeos Therapeutics regains rights to IDO1 inhibitor

Belgium-based iTeos Therapeutics SA has regained rights to an early-stage cancer drug from Pfizer Inc which was being investigated in a Phase 1 trial as a potential single agent for treating patients with malignant gliomas.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Syndicate content